Abstract: The disclosure provided herein relates to monospecific and multispecific anti-TMEFF2 antibodies, and methods of producing and using the described antibodies.

Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Abstract: The disclosure provided herein relates to monospecific and multispecific anti-TMEFF2 antibodies, and methods of producing and using the described antibodies.

Abstract: The present invention relates to purified compositions of bee bloom, methods of preparing the purified compositions of bee bloom and the use of bee bloom in the reducing and treatment of inflammation.

Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Abstract: The present invention relates to purified compositions of bee bloom, methods of preparing the purified compositions of bee bloom and the use of bee bloom in the reducing and treatment of inflammation.

Abstract: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).

Abstract: A process (20) and design tool (62) are presented for the accurate prediction of design parameters (42) for components (38) of an integrated circuit (22) during the early stages of the design of that integrated circuit (22). These predicted design parameters (42) include pin count parameters (50), propagation delay parameters (52), layout area parameters (54), dynamic power parameters (56), static power parameters (58), and total power parameters (60). With these parameters, the designer interactively modifies the design prior to the layout and prototyping of the integrated circuit (22). The dynamic power parameters (56) and total power parameters (60) may be repetitively predicted with differing input items to establish a power usage pattern for the integrated circuit (22).

Abstract: A process (20) and design tool (62) are presented for the accurate prediction of design parameters (42) for components (38) of an integrated circuit (22) during the early stages of the design of that integrated circuit (22). These predicted design parameters (42) include pin count parameters (50), propagation delay parameters (52), layout area parameters (54), dynamic power parameters (56), static power parameters (58), and total power parameters (60). With these parameters, the designer interactively modifies the design prior to the layout and prototyping of the integrated circuit (22). The dynamic power parameters (56) and total power parameters (60) may be repetitively predicted with differing input items to establish a power usage pattern for the integrated circuit (22).

Abstract: A process (20) is presented for determining the total routine energy (78) consumed by a processor (22) during the execution of a code routine (36). This total routine energy (78) is computed by determining the operation energy (76) consumed in the execution of each operating instruction (38) within the code routine (36). The operation energy (76) for each operating instruction (38) is computed by determining the average operation power (74) consumed during the execution of the operating instruction (38). The average operation power (74) for each operating instruction (38) is determined by determining an instruction power (90) and a summed-action power (92) for that operating instruction (38). The summed-action power (92) is the sum of action powers (96) computed through the use of an action formula (100) for each internal action (88) performed by the processor (22) in response to the operating instruction (38).